This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
100
ASC30 tablets administered orally once daily
Placebo administered orally once daily
Ascletis Clinical Site
Riverside, California, United States
Ascletis Clinical Site
San Jose, California, United States
Ascletis Clinical Site
Denver, Colorado, United States
Ascletis Clinical Site
Miami, Florida, United States
Mean change from baseline in HbA1c up to 13 weeks in the treatment group compared with the placebo group
Time frame: Baseline and end of Week 13
Mean change from baseline in fasting blood glucose up to 13 weeks in the treatment group compared with the placebo group
Time frame: Baseline and end of Week 13
Mean change from baseline in body weight up to 13 weeks in the treatment group compared with placebo group
Time frame: Baseline and end of Week 13
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ascletis Clinical Site
Miami, Florida, United States
Ascletis Clinical Site
Decatur, Georgia, United States
Ascletis Clinical Site
Springfield, Missouri, United States
Ascletis Clinical Site
San Antonio, Texas, United States